Jun 8, 2005|
Nicholas Piramal: Where to from here?
Domestic pharma major, Nicholas Piramal announced disappointing FY05 results due to VAT related concerns. In this article, we take a look at how the company has performed over the years and future prospects.
Nicholas Piramal is one of the leading Indian pharma companies with strong focus in the domestic market. It is the 4th largest company with 4.3% market share (FY05) in the domestic market with a large sales force covering 10 therapeutic segments of the pharma industry. The company has started focusing on the exports market too and the contribution of exports in total sales has increased to 12% from zero in the space of three years. It has gradually improved its product portfolio by increasing the share of lifestyle drugs and has also started focusing on R&D off late. The biggest contributor to company's revenue is respiratory and cardiovascular segment. The other major therapeutic segments in which the company operates are anti-infectives, nutritional, and gastro intestinal.
How the numbers stack up
|Operating profit (EBIDTA)
|Operating profit margin (%)
|Profit before tax
|Profit after tax
|Net profit margin (%)
|No. of shares (m)
|Diluted earnings per share (Rs)*
|P/E ratio (x)
FY03: Topline registered a 20% YoY growth largely driven by the formulations business. The company grew faster than the market in 7 of the 9 main therapeutic areas in which it has a presence. Due to its focus on the lifestyle segment, the exposure to the slowly growing anti-infectives segment was reduced. The company aggressively launched 21 new products during the year out of which 14 were in the lifestyle segment. Operating margins increased from 16% to 18% on the back of increased revenues aided by benefits arising from the integration of ICI India's pharma division with Nicholas and continuous cost cutting efforts.
| The journey over the years...|
Bottomline jumped 145% YoY aided by lower interest costs and tax outgo. Interest burden reduced due to substantial repayment of debt and substitution of high cost with low cost debt.
FY04: Topline during the year clocked a robust 33% YoY growth propelled by growth in the domestic branded formulations business and exports. Exports contributed about 8.5% of the total revenues in FY04, which was aided by a huge surge in API exports mostly to the US and European markets. However, it must be noted that some part of this growth came from the merger of Sarabhai Piramal Pharmaceuticals with itself. If one were to consider the organic growth (without considering the Sarabhai merger), the company grew by 17% YoY while the growth in formulations business was 13% against the overall growth of 7.3% of the domestic market for FY04.
The company outperformed the market in 9 out of 10 therapeutic areas in which it operates and the overall market for lifestyle drugs grew faster than other therapeutic segments in the domestic market. Operating margins improved from 18% to 20%. This was despite the 79% rise in R&D expenditure. Bottomline registered a 59% YoY growth on account of lower interest costs, higher operating efficiency and a tax write-back. During the year, the company launched 23 new products.
FY05: Nicholas witnessed a drop in revenues by 2% YoY, which was due to VAT-led de-stocking and retailers' industry-wide boycott relating to psychotropic and narcotic drugs. The company continued its focus on the high growth lifestyle segment, which constituted 27% of sales. Respiratory drugs continued to dominate the branded formulations segment (22% of sales). Despite savings in material cost, increased R&D spend aided the 5% YoY rise in expenditure. The R&D spend as a percentage of sales rose from 2% in FY04 to 4% in FY05. However, it must be noted that lower offtake also skewed this ratio. Operating margins dipped by 420 basis points chiefly on account of reduced sales.
During the year, the company snapped ties with Roche Diagnostics and received consideration to the tune of Rs 862 m. This provided a cushion to the bottomline which fell 10% YoY. But for this receipt, the fall in the bottomline would have been much sharper. Also, the company acquired the global Inhalation Anaesthetics (IA) business from Rhodia Organique Fine, which will give it access to the manufacturing technology and facilities as well as global sales and marketing rights for IA products. 35 new products were launched by the company in FY05.
At Rs 264, the stock is trading at a P/E of 26 times its estimated FY08 earnings. Contract manufacturing is going to be the growth driver for the company going forward. The company secured 2 agreements (one with a Fortune 500 company and the other with Allergan Inc. USA). Also, negotiations are underway to secure 2 more such contracts.
Now that India has begun to realise product patents, it remains to be seen how Nicholas will cope with the same in the long term, as majority of the company's revenues is derived from the domestic market. The company will find it difficult to introduce new products at the same rate like it had done in the past. Despite the increase in R&D spend, we believe that the company is unlikely to make any significant breakthrough on the R&D front in the next 3-4 years.
We had given a Sell recommendation on the stock on January 1, 2005. In view of the high valuations, investors are better off keeping away from the stock.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407